Table 3.
Analysis of factors associated with disease progression including biomarker fold-change values
| Variable | UVA |
MVA |
||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Sex (female vs. male) | 0.94 | 0.55–1.62 | 0.832 | |||
| Tumor number (multiple vs. one) | 1.91 | 1.19–3.08 | 0.007 | |||
| Liver cirrhosis (yes vs. no) | 1.00 | 0.63–1.58 | 0.989 | |||
| Child-pugh class (B vs. A) | 1.40 | 0.70–2.83 | 0.345 | |||
| Concurrent chemotherapy (no vs. yes) | 0.99 | 0.62–1.62 | 0.989 | |||
| PVTT (yes vs. no) | 1.33 | 0.84–2.10 | 0.225 | |||
| Previous treatment (yes vs. no) | 1.34 | 0.85–2.12 | 0.207 | 3.14 | 1.71–5.79 | <0.001 |
| Age (>60 vs. ≤60) | 1.01 | 0.64–1.60 | 0.953 | 0.37 | 0.15–0.90 | 0.029 |
| Tumor size (>6.5 cm vs. ≤6.5 cm) | 1.01 | 0.64–1.60 | 0.964 | |||
| Lymph node metastasis (yes vs. no) | 0.95 | 0.41–2.19 | 0.896 | |||
| Treatment aim (salvage vs. definitive) | 1.15 | 0.73–1.82 | 0.551 | |||
| UICC stage | 0.088 | 0.001 | ||||
| III versus II | 1.66 | 0.91–3.04 | 0.100 | 2.72 | 1.40–5.30 | 0.003 |
| IV versus II | 1.92 | 1.07–3.46 | 0.030 | 3.47 | 1.73–6.98 | <0.001 |
| AFP (>71.13 ng/mL vs. ≤71.13 ng/mL) | 1.41 | 0.89–2.22 | 0.146 | |||
| PIVKA-II (>1,629 mAU/mL vs. ≤1,629 mAU/mL) | 1.35 | 0.85–2.13 | 0.207 | 1.76 | 0.99–3.09 | 0.052 |
| sPD-L1 fold change | 1.01 | 1.00–1.03 | 0.062 | 1.02 | 1.00–1.03 | 0.023 |
| IL-6 fold change | 0.98 | 0.94–1.03 | 0.460 | |||
| IL-10 fold change | 1.07 | 0.82–1.38 | 0.622 | |||
| ITIH4 fold change | 1.09 | 0.89–1.72 | 0.721 | |||
| cfDNA fold change | 1.07 | 0.99–1.17 | 0.106 | 1.12 | 1.01–1.24 | 0.029 |
PVTT, portal vein tumor thrombosis; UICC, Union for International Cancer Control.